KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $201.2 million.

  • Sarepta Therapeutics' Net Income towards Common Stockholders rose 285875.0% to $201.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $360.0 million, marking a year-over-year increase of 19291.94%. This contributed to the annual value of $235.0 million for FY2024, which is 14382.98% up from last year.
  • Sarepta Therapeutics' Net Income towards Common Stockholders amounted to $201.2 million in Q2 2025, which was up 285875.0% from $158.8 million recorded in Q4 2024.
  • Sarepta Therapeutics' 5-year Net Income towards Common Stockholders high stood at $201.2 million for Q2 2025, and its period low was -$516.8 million during Q1 2023.
  • In the last 5 years, Sarepta Therapeutics' Net Income towards Common Stockholders had a median value of -$48.1 million in 2021 and averaged -$71.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 85615.14% in 2021, then soared by 285875.0% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Net Income towards Common Stockholders stood at -$122.0 million in 2021, then rose by 9.94% to -$109.9 million in 2022, then soared by 141.44% to $45.5 million in 2023, then soared by 248.8% to $158.8 million in 2024, then rose by 26.7% to $201.2 million in 2025.
  • Its Net Income towards Common Stockholders was $201.2 million in Q2 2025, compared to $158.8 million in Q4 2024 and $34.0 million in Q3 2024.